Browse all clinical evidence, news, and expert commentary
A UK observational study of more than 8,000 women found substantial six-month weight loss and high retention in a structured digital-first GLP-1 programme. It is promising implementation evidence, but not a comparison with NHS or face-to-face care.
Dr Saira Bano explains why BMI is a starting point—not the whole assessment—and how waist-to-height ratio, HbA1c, blood pressure, lipids and cardiovascular risk help build a clearer metabolic picture in primary care.
Preclinical studies show sustained molecular responses to GLP-1 receptor stimulation in pancreatic cell models. What does that mean for primary care, and what does it not show?
A BMJ network meta-analysis of 262 trials and 99,791 participants compares 19 obesity drugs. The ranking matters less than what sits behind each position.
A triple agonist is a single peptide with activity at the GLP-1, GIP and glucagon receptors. This animation maps where each one acts and what the early trial evidence shows.
Three NICE pathways for the same class of drug, each with its own eligibility criteria, funding route, and stopping rule. Kashif Shakoor maps a practical route through the complexity.
ATTAIN-MAINTAIN, published in Nature Medicine, shows that switching from injectable GLP-1 receptor agonists to oral orforglipron preserves over 74% of weight loss at 52 weeks.[1] Here is what the data shows and what it means for primary care.
Surgery still outperforms pharmacotherapy for sustained weight loss. The gap widens once therapy stops. A practical synthesis for UK primary care prescribers.
How GLP-1 receptor agonists drive weight loss across the brain, gut, and metabolism.
If you prescribe semaglutide, you need to know about this MHRA safety update on the risk of rare vision loss.
If it feels like your practice is increasingly dominated by patients asking for the 'miracle jab,' you aren't alone. A comprehensive primary care update on GLP-1 receptor agonists in 2026.
